1-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrazole-3-carboxylic acid | 1006962-72-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrazole-3-carboxylic acid
• 英文别名: 1-[5-(trifluoromethyl)pyridin-2-yl]pyrazole-3-carboxylic acid
• CAS: 1006962-72-6
• 化学式: C₁₀H₆F₃N₃O₂
• mdl: MFCD08696966
• 分子量: 257.17
• InChiKey: CSRAZBQUAVXIOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] PYRAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012168260A1

  公开（公告）日：2012-12-13

  The invention relates to compounds of formula wherein R1 is hydrogen or phenyl, optionally substitutes by halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen or lower alkyl or is phenyl optionally substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen; R4 is hydrogen, lower alkyl or phenyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式中的化合物，其中R1是氢或苯基，可选择由卤素、CN或较低的烷氧基或由卤素取代的较低的烷氧基取代；R2是氢或较低的烷基；R3是氢或较低的烷基或是苯基，可选择由卤素、氰基或由卤素取代的较低的烷氧基取代，或是吡啶基，可选择由卤素或由卤素取代的较低的烷基取代，或是嘧啶基，可选择由较低的烷基取代的较低的烷基取代，或是吡嗪基，可选择由卤素、氰基或由卤素取代的较低的烷基取代；R4是氢、较低的烷基或苯基；Z是键，-CH2-或-O-；或其药学上适宜的酸盐。现已发现，IA和IB式的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的疾病、如精神分裂症等精神疾病、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2014068988A1

  公开（公告）日：2014-05-08

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑并吡啶衍生物，这些衍生物具有阻断TTX-S型电压门控钠通道的活性，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
• PYRAZOLE DERIVATIVES
  申请人：Galley Guido

  公开号：US20120316172A1

  公开（公告）日：2012-12-13

  The invention relates to compounds of formula IA and IB wherein R 1 , R 2 , R 3 , R 4 and Z are as defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及式IA和IB的化合物，其中R1、R2、R3、R4和Z如本文所定义，或其药学上适宜的酸盐。式IA和IB的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS
  申请人：RAQUALIA PHARMA INC.

  公开号：US20150291582A1

  公开（公告）日：2015-10-15

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑吡啶衍生物，其具有钠离子电压门控通道的阻滞活性，包括TTX-S通道，并且可用于治疗或预防涉及钠离子电压门控通道的疾病和疾病。本发明还涉及包括这些化合物的制药组合物以及在预防或治疗涉及钠离子电压门控通道的疾病中使用这些化合物和组合物的用途。
• US9073911B2
  申请人：——

  公开号：US9073911B2

  公开（公告）日：2015-07-07